calcium acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4287	62-54-4

Description:

Molecule	Description
Synonyms: calcium acetate acetic acid calcium salt calcium diacetate calcium acetate anhydrous	a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer Molecular weight: 158.17 Formula: C4H6CaO4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 40.13 ALOGS: ROTB: None

Molecule

Description

Synonyms:

calcium acetate
acetic acid calcium salt
calcium diacetate
calcium acetate anhydrous

a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer

Molecular weight: 158.17
Formula: C4H6CaO4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 40.13
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
6	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 6, 1982	FDA	B BRAUN

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	265.95	13.93	72	9232	4484	63475234
Skin induration	120.55	13.93	36	9268	3187	63476531
Peritonitis bacterial	117.76	13.93	39	9265	4840	63474878
Skin hypertrophy	97.68	13.93	31	9273	3360	63476358
Calciphylaxis	92.29	13.93	29	9275	3043	63476675
Skin tightness	82.61	13.93	29	9275	4287	63475431
Skin fibrosis	61.28	13.93	16	9288	864	63478854
Chronic kidney disease	59.64	13.93	51	9253	45347	63434371
Peritonitis	57.12	13.93	34	9270	17120	63462598
Skin hyperpigmentation	50.02	13.93	22	9282	5899	63473819

Showing 1 to 10 of 67 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	227.64	16.34	70	8789	3935	34944137
Peritonitis bacterial	157.51	16.34	59	8800	6051	34942021
Skin induration	123.91	16.34	38	8821	2113	34945959
Skin hypertrophy	112.37	16.34	37	8822	2592	34945480
Skin tightness	93.45	16.34	31	8828	2222	34945850
Joint contracture	85.42	16.34	28	8831	1933	34946139
Joint range of motion decreased	75.70	16.34	37	8822	7275	34940797
Skin fibrosis	70.99	16.34	21	8838	1031	34947041
Peritonitis	59.47	16.34	42	8817	16323	34931749
Scar	58.32	16.34	29	8830	5915	34942157

Showing 1 to 10 of 47 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	351.25	14.15	100	14310	6060	79723918
Peritonitis bacterial	271.68	14.15	91	14319	9476	79720502
Skin induration	181.62	14.15	56	14354	4469	79725509
Skin hypertrophy	172.77	14.15	55	14355	4873	79725105
Skin tightness	150.72	14.15	51	14359	5471	79724507
Calciphylaxis	131.84	14.15	42	14368	3728	79726250
Peritonitis	116.40	14.15	69	14341	27967	79702011
Skin fibrosis	106.35	14.15	29	14381	1495	79728483
Joint contracture	100.28	14.15	31	14379	2493	79727485
Chronic kidney disease	82.29	14.15	79	14331	66075	79663903

Showing 1 to 10 of 87 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V03AE07	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
CHEBI has role	CHEBI:38161	Chelating agent
MeSH PA	D002614	Chelating Agents
MeSH PA	D064449	Sequestering Agents

Showing 1 to 4 of 4 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypocalcemia	indication	5291005
Hyperkalemia	indication	14140009
Hypermagnesemia	indication	66978005
Hypocalcemic tetany	indication	190869004
Disorder of electrolytes	indication	237840007
Cardiac arrest	indication	410429000	DOID:0060319
Renal Osteodystrophy with Hyperphosphatemia	indication
Neonatal hypocalcemic tetany	off-label use	18442000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335

Showing 1 to 10 of 21 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8592480	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	9089528	July 20, 2027	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
667MG/5ML	PHOSLYRA	FRESENIUS MEDCL	N022581	April 18, 2011	DISCN	SOLUTION	ORAL	8591938	Feb. 23, 2030	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

Showing 1 to 3 of 3 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
000772	NDDF
116118002	SNOMEDCT_US
118	MMSL
214342	RXNORM
387019008	SNOMEDCT_US
4018721	VUID
4018721	VANDF
4329	MMSL
6116	PUBCHEM_CID
C0717537	UMLSCUI

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Aluminum Acetate Astringent	HUMAN OTC DRUG LABEL	2	51224-153	POWDER, FOR SOLUTION	839 mg	TOPICAL	OTC MONOGRAPH FINAL	13 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0088	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8364	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2081	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2081	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2672	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2672	CAPSULE	667 mg	ORAL	NDA authorized generic	26 sections
CALCIUM ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6668	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7119	CAPSULE	667 mg	ORAL	ANDA	25 sections
Calcium Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-629	CAPSULE	667 mg	ORAL	ANDA	26 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next